Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease

키워드

참고문헌 (98)

1. Celermajer DS, "Cardiovascular disease in the developing world : prevalences, patterns, and the potential of early disease detection", J Am Coll Cardiol, 60, pp.1207~1216 (2012)
2. Sonoda H, "Uric acid levels predict future development of chronic kidney disease", Am J Nephrol, 33, pp.352~357 (2011)
3. Rakic MT, "Observations on the natural history of hyperuricemia and gout. I. an eighteen year follow-up of nineteen gouty families", Am J Med, 37, pp.862~871 (1964)
4. Grayson PC, "Hyperuricemia and incident hypertension : a systematic review and meta-analysis", Arthritis Care Res (Hoboken), 63, pp.102~110 (2011)
5. Kang DH, "A role for uric acid in the progression of renal disease", J Am Soc Nephrol, 13, pp.2888~2897 (2002)
6. Song P, "Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China", Sci Rep, 8, pp.4314~ (2018)
7. Li Z, "Gender difference in the association of hyperuricemia with chronic kidney disease in southern China", Kidney Blood Press Res, 36, pp.98~106 (2012)
8. Japanese Society of Gout and Nucleic Acid Metabolism, "Guideline for the Management of Hyperuricemia and Gout" (2010), Medical Review
9. Gavin AR, "Hyperuricemia and adverse outcomes in cardiovascular disease : potential for therapeutic intervention", Am J Cardiovasc Drugs, 3, pp.309~314 (2003)
10. Madero M, "Uric acid and longterm outcomes in CKD", Am J Kidney Dis, 53, pp.796~803 (2009)
11. Kuwabara M, "Hyperuricemia, cardiovascular disease, and hypertension", Pulse (Basel), 3, pp.242~252 (2016)
12. Kumagai T, "Time to target uric acid to retard CKD progression", Clin Exp Nephrol, 21, pp.182~192 (2017)
13. Ryu ES, "Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease", Am J Physiol Renal Physiol, 304, pp.F471~F480 (2013)
14. Ilundain-Gonzalez AI, "Impact of uric acid levels on the risk of long-term cardiovascular mortality in patients with type 2 diabetes mellitus", Endocrinol Diabetes Nutr, 65, pp.335~341 (2018)
15. Johnson RJ, "Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation", Am J Kidney Dis, 71, pp.851~865 (2018)
16. Faruque LI, "A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout", Semin Arthritis Rheum, 43, pp.367~375 (2013)
17. White WB, "Cardiovascular safety of febuxostat or allopurinol in patients with gout", N Engl J Med, 378, pp.1200~1210 (2018)
18. U.S. Food and Drug Administration, "Uloric (febuxostat)Drug Safety Communication: FDA to Evaluate Increased Risk of Heart-related Death" (2018), FDA
19. "FDA adds Boxed Warning for increased risk of death with gout medicine uloric (febuxostat)" (2019)[URL]
20. Alegria-Diaz A, "Clinical significance of serum uric acid levels in Mexican young adults", Contrib Nephrol, 192, pp.125~134 (2018)
21. Kutzing MK, "Altered uric acid levels and disease states", J Pharmacol Exp Ther, 324, pp.1~7 (2008)
22. 강덕희, "Uric Acid Puzzle: Dual Role as Anti-oxidantand Pro-oxidant", Electrolytes & Blood Pressure, 12(1), pp.1~6 (2014), 전해질고혈압연구회[DOI]
23. Carvalho LAC, "Uric acid disrupts hypochlorous acid production and the bactericidal activity of HL-60 cells", Redox Biol, 16, pp.179~188 (2018)
24. Kaplan JM, "Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease", Int J Mol Sci, 19, pp.389~ (2018)
25. Eleftheriadis T, "Allopurinol protects human glomerular endothelial cells from high glucose-induced reactive oxygen species generation, p53 overexpression and endothelial dysfunction", Int Urol Nephrol, 50, pp.179~186 (2018)
26. Johnson RJ, "Potential role of sugar(fructose)in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease", Am J Clin Nutr, 86, pp.899~906 (2007)
27. Ross EA, "Renal function and urate metabolism in late survivors with cyanotic congenital heart disease", Circulation, 73, pp.396~400 (1986)
28. Maiuolo J, "Regulation of uric acid metabolism and excretion", Int J Cardiol, 213, pp.8~14 (2016)
29. Andrade Sierra J, "Renal handling of uric acid", Contrib Nephrol, 192, pp.1~7 (2018)
30. Enomoto A, "Molecular identification of a renal urate anion exchanger that regulates blood urate levels", Nature, 417, pp.447~452 (2002)
31. Ikarashi R, "Immunohistochemical studies of organic anion transporters and urate transporter 1 expression in human salivary gland", Acta Odontol Scand, 71, pp.312~316 (2013)
32. Wallace C, "Genome-wide association study identifies genes for biomarkers of cardiovascular disease : serum urate and dyslipidemia", Am J Hum Genet, 82, pp.139~149 (2008)
33. Wright AF, "A ‘complexity’of urate transporters", Kidney Int, 78, pp.446~452 (2010)
34. Otani N, "Roles of organic anion transporters(OATs)in renal proximal tubules and their localization", Anat Sci Int, 92, pp.200~206 (2017)
35. Xu L, "Recent advances on uric acid transporters", Oncotarget, 8, pp.100852~100862 (2017)
36. Seki S, "Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension", Clin Exp Hypertens, 32, pp.270~277 (2010)
37. Sundstrom J, "Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence", Hypertension, 45, pp.28~33 (2005)
38. Mellen PB, "Serum uric acid predicts incident hypertension in a biethnic cohort : the atherosclerosis risk in communities study", Hypertension, 48, pp.1037~1042 (2006)
39. Mazzali M, "Uric acid and hypertension: cause or effect?", Curr Rheumatol Rep, 12, pp.108~117 (2010)
40. Doehner W, "Uric acid as a prognostic marker in acute heart failure : new expectations from an old molecule", Eur J Heart Fail, 9, pp.437~439 (2007)
41. Forman JP, "Uric acid and insulin sensitivity and risk of incident hypertension", Arch Intern Med, 169, pp.155~162 (2009)
42. Moriel P, "Nitric oxide, cholesterol oxides and endothelium-dependent vasodilation in plasma of patients with essential hypertension", Braz J Med Biol Res, 35, pp.1301~1309 (2002)
43. Jossa F, "Serum uric acid and hypertension : the Olivetti heart study", J Hum Hypertens, 8, pp.677~681 (1994)
44. Price KL, "Human vascular smooth muscle cells express a urate transporter", J Am Soc Nephrol, 17, pp.1791~1795 (2006)
45. Oguz N, "Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells", J Recept Signal Transduct Res, 37, pp.500~505 (2017)
46. Kirca M, "Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44", 42MAPK and PDGFRβ, 2017, pp.37, 167~173
47. Kohjimoto Y, "Metabolic syndrome and nephrolithiasis", Hinyokika Kiyo, 57, pp.43~47 (2011)
48. Huang Y, "Rosiglitazone alleviates injury in rats with adenine-induced chronic kidney disease", Mol Med Rep, 8, pp.1831~1835 (2013)
49. Coresh J, "Prevalence of chronic kidney disease in the United States", JAMA, 298, pp.2038~2047 (2007)
50. Iseki K, "Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort", Am J Kidney Dis, 44, pp.642~650 (2004)
51. Weiner DE, "Uric acid and incident kidney disease in the community", J Am Soc Nephrol, 19, pp.1204~1211 (2008)
52. Chonchol M, "Relationship of uric acid with progression of kidney disease", Am J Kidney Dis, 50, pp.239~247 (2007)
53. Lin B, "Prevalence of chronic kidney disease and its association with metabolic diseases : a cross-sectional survey in Zhejiang province, Eastern China", BMC Nephrol, 15, pp.36~ (2014)
54. Hsu CY, "Risk factors for end-stage renal disease : 25-year follow-up", Arch Intern Med, 169, pp.342~350 (2009)
55. Kang DH, "Hyperuricemia and progression of chronic kidney disease : role of phenotype transition of renal tubular and endothelial cells", Contrib Nephrol, 192, pp.48~55 (2018)
56. Feig DI, "Uric acid and cardiovascular risk", N Engl J Med, 359, pp.1811~1821 (2008)
57. Johnson RJ, "Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?", Hypertension, 41, pp.1183~1190 (2003)
58. Cai W, "Uric acid induces endothelial dysfunction by activating the HMGB1", RAGE signaling pathway, 2017, pp.2017, 4391920~
59. Zhang JX, "Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes", Endocrine, 48, pp.135~142 (2015)
60. Feig DI, "Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension : a randomized trial", JAMA, 300, pp.924~932 (2008)
61. Kimura K, "Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia : a randomized trial", Am J Kidney Dis, 72, pp.798~810 (2018)
62. Sircar D, "Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia : a 6-month, double-blind, randomized, placebo-controlled trial", Am J Kidney Dis, 66, pp.945~950 (2015)
63. Siu YP, "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level", Am J Kidney Dis, 47, pp.51~59 (2006)
64. Goicoechea M, "Effect of allopurinol in chronic kidney disease progression and cardiovascular risk", Clin J Am Soc Nephrol, 5, pp.1388~1393 (2010)
65. Yu H, "Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease : a prospective pilot study", Clin Exp Nephrol, 22, pp.1324~1330 (2018)
66. Chou HW, "Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia : a 13-year inception cohort study", Nephrol Dial Transplant, 33, pp.1620~1627 (2018)
67. Kanbay M, "Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions", Int Urol Nephrol, 39, pp.1227~1233 (2007)
68. Momeni A, "Effect of allopurinol in decreasing proteinuria in type 2diabetic patients", Iran J Kidney Dis, 4, pp.128~132 (2010)
69. Pai BH, "Allopurinol for prevention of progression of kidney disease with hyperuricemia", Indian J Nephrol, 23, pp.280~286 (2013)
70. Sezer S, "Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia", Saudi J Kidney Dis Transpl, 25, pp.316~320 (2014)
71. Liu X, "The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5", Clin Exp Nephrol, 23, pp.362~370 (2019)
72. Gagliardi AC, "Uric acid : a marker of increased cardiovascular risk", Atherosclerosis, 202, pp.11~17 (2009)
73. Stack AG, "Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality", QJM, 106, pp.647~658 (2013)
74. Messerli FH, "Serum uric acid in essential hypertension : an indicator of renal vascular involvement", Ann Intern Med, 93, pp.817~821 (1980)
75. Alderman MH, "Serum uric acid and cardiovascular events in successfully treated hypertensive patients", Hypertension, 34, pp.144~150 (1999)
76. Alderman MH, "Serum uric acid as a cardiovascular risk factor for heart disease", Curr Hypertens Rep, 3, pp.184~189 (2001)
77. Verdecchia P, "Relation between serum uric acid and risk of cardiovascular disease in essential hypertension", Hypertension, 36, pp.1072~1078 (2000)
78. Ward HJ, "Uric acid as an independent risk factor in the treatment of hypertension", Lancet, 352, pp.670~671 (1998)
79. Okura T, "Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis : subanalysis of the Japanese Coronary Artery Disease(JCAD)Study", Circ J, 73, pp.885~891 (2009)
80. Tamariz L, "Association between serum uric acid and atrial fibrillation : a systematic review and meta-analysis", Heart Rhythm, 11, pp.1102~1108 (2014)
81. study), "Am J Cardiol", 2011, 1272~1276
82. Jun JE, "Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors", Atherosclerosis, 272, pp.233~239 (2018)
83. Tamariz L, "Uric acid as a predictor of all-cause mortality in heart failure : a meta-analysis", Congest Heart Fail, 17, pp.25~30 (2011)
84. Thanassoulis G, "Gout, allopurinol use, and heart failure outcomes", Arch Intern Med, 170, pp.1358~1364 (2010)
85. Schlesinger N, "Management of acute and chronic gouty arthritis : present state-of-the-art", Drugs, 64, pp.2399~2416 (2004)
86. Becker MA, "Febuxostat compared with allopurinol in patients with hyperuricemia and gout", N Engl J Med, 353, pp.2450~2461 (2005)
87. Beberashvili I, "Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients", Nutrition, 31, pp.138~147 (2015)
88. Culleton BF, "Serum uric acid and risk for cardiovascular disease and death : the Framingham Heart Study", Ann Intern Med, 131, pp.7~13 (1999)
89. Jee SH, "Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men", Eur J Cardiovasc Prev Rehabil, 11, pp.185~191 (2004)
90. Gordon T, "Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study", Arch Intern Med, 143, pp.1366~1374 (1983)
91. Fang J, "Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey", JAMA, 283, pp.2404~2410 (2000)
92. Ndrepepa G, "A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease", Nutr Metab Cardiovasc Dis, 23, pp.1195~1201 (2013)
93. Tuttle KR, "Sex differences in uric acid and risk factors for coronary artery disease", Am J Cardiol, 87, pp.1411~1414 (2001)
94. Kim SY, "Hyperuricemia and coronary heart disease : a systematic review and meta-analysis", Arthritis Care Res (Hoboken), 62, pp.170~180 (2010)
95. Niskanen LK, "Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men : a prospective cohort study", Arch Intern Med, 164, pp.1546~1551 (2004)
96. Ohyama Y, "Impact of uric acid on incident hypertension : sex-specific analysis in different age groups", Int J Cardiol Hypertens, 2, pp.100009~ (2019)
97. Kang E, "Sex-specific relationship of serum uric acid with all-cause mortality in adults with normal kidney function : an observational study", J Rheumatol, 44, pp.380~387 (2017)
98. Conen D, "Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country", BMC Public Health, 4, pp.9~ (2004)

관련 논문AI추천